Products - Bladder cancer | Topic | NICE

Showing 15 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation) (TA1163)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 June 2026
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) (TA1141)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2026
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer (TA1138)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 March 2026
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (TA1097)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2025
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 May 2025
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 May 2022
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2013